Nautilus Biotechnology (NASDAQ:NAUT) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Nautilus Biotechnology (NASDAQ:NAUT) to a hold rating in a report released on Wednesday,Zacks reports.

A number of other equities research analysts have also recently commented on NAUT. Leerink Partners assumed coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 target price for the company. Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Finally, Roth Capital assumed coverage on shares of Nautilus Biotechnology in a research note on Tuesday. They set a “buy” rating and a $3.50 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nautilus Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $3.83.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock opened at $1.57 on Wednesday. The stock has a market capitalization of $199.78 million, a P/E ratio of -3.49 and a beta of 0.73. The business has a 50 day simple moving average of $1.01 and a two-hundred day simple moving average of $2.01. Nautilus Biotechnology has a 12 month low of $0.82 and a 12 month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million. As a group, research analysts anticipate that Nautilus Biotechnology will post -0.52 EPS for the current fiscal year.

Institutional Trading of Nautilus Biotechnology

Large investors have recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. increased its stake in shares of Nautilus Biotechnology by 1,500.0% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after acquiring an additional 15,000 shares during the last quarter. CTC Alternative Strategies Ltd. purchased a new stake in shares of Nautilus Biotechnology in the first quarter valued at about $48,000. Callan Family Office LLC acquired a new stake in Nautilus Biotechnology during the second quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in Nautilus Biotechnology during the second quarter worth about $63,000. Finally, AXQ Capital LP purchased a new position in Nautilus Biotechnology during the second quarter worth about $64,000. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.